AN2 Therapeutics Inc (ANTX) - Total Liabilities
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has total liabilities worth $8.89 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of AN2 Therapeutics Inc to track the company's year-over-year net asset growth rate.
AN2 Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
AN2 Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of AN2 Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sajo Ind
KO:007160
|
Korea | ₩617.05 Billion |
|
Reit Azorim HF Living Ltd
TA:AZRT
|
Israel | ILA2.19 Billion |
|
IZMO Limited
NSE:IZMO
|
India | Rs848.53 Million |
|
Media Capital
LS:MCP
|
Portugal | €100.75 Million |
|
S-Oil Corp Pref
KO:010955
|
Korea | ₩16.34 Trillion |
|
Terra Metals Ltd
AU:TM1
|
Australia | AU$1.02 Million |
|
Mechema Chemicals Int
TWO:4721
|
Taiwan | NT$843.04 Million |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$7.55 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down AN2 Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AN2 Therapeutics Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AN2 Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of AN2 Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.89 Million | -13.17% |
| 2024-12-31 | $10.24 Million | -27.10% |
| 2023-12-31 | $14.04 Million | +95.37% |
| 2022-12-31 | $7.19 Million | +110.92% |
| 2021-12-31 | $3.41 Million | +129.80% |
| 2020-12-31 | $1.48 Million | +67.19% |
| 2019-12-31 | $887.00K | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more